This technology is a therapeutic approach that uses a low dose of nicotinamide to lower intraocular pressure (IOP), which, when elevated, is an important risk factor for glaucoma.
Glaucoma affects millions globally and can be caused by the buildup of intraocular pressure (IOP), causing optic nerve damage and progressive blindness. Because glaucoma is often detected after damage has occurred, it is critical to monitor and reduce high IOP at the earliest stage. Current treatments focus on reducing IOP through topical eye application, which is difficult and time-consuming for patients. Therefore, there is a need for a cost-effective, easy-to-use preventive approach to reduce high IOP with minimal side effects.
This technology identifies low doses of nicotinamide to relieve high intraocular pressure (IOP) and slow the progression of glaucoma. Unlike existing treatments, nicotinamide can be easily taken orally in food or drink. Low doses of nicotinamide support fluid drainage from the eye and reduce IOP, which helps prevent worsening glaucoma. Nicotinamide is also shown to be effective in hard-to-treat cases where glaucoma is linked to underlying genetic mutations, supporting its use for a wider range of patients.
Nicotinamide and pyruvate use in tandem has been validated in Phase 2 randomized clinical trials, demonstrating a reduction in IOP and significant short-term improvement in visual function.
Patent Pending (WO/2024/243081, US20260053789)
IR CU23299
Licensing Contact: Kristin Neuman
